STAAR Surgical Company reaffirmed sales guidance for the year 2022. For the year, the company reaffirming previously provided outlook for fiscal 2022 net sales of approximately $295 million, which takes into account a significant currency headwind and a continuation of the current level of COVID-19 related challenges in China and elsewhere, offset by stronger than expected demand for EVO lenses, which has continued through the beginning of the third quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.57 USD | +2.88% | -5.24% | +39.60% |
May. 08 | Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating | MT |
May. 08 | Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.60% | 2.14B | |
-4.82% | 182B | |
+1.38% | 111B | |
-2.82% | 68.48B | |
+0.69% | 49.69B | |
+8.54% | 44.46B | |
+2.10% | 40.67B | |
+20.50% | 31.22B | |
+1.72% | 26.09B | |
+14.78% | 25.32B |
- Stock Market
- Equities
- STAA Stock
- News STAAR Surgical Company
- STAAR Surgical Company Re-Affirms Sales Guidance for the Year 2022